Historically a Democratic focus, drug pricing policy has been co-opted by Republicans, making it a bipartisan political issue. This alignment creates a stable policy overhang and sustained uncertainty around pricing and innovation, deterring generalist investors regardless of which party is in power.
Beyond tackling fatal diseases to increase lifespan, a new wave of biotech innovation focuses on "health span"—the period of life lived in high quality. This includes developing treatments for conditions often dismissed as aging, such as frailty, vision loss, and hearing decline, aiming to improve wellbeing in later decades.
While healthcare companies widely use AI for cost savings and R&D efficiency, it has not yet translated into measurable revenue or earnings growth. For equity investors, there are easier, more direct ways to invest in the AI trend, making healthcare a poor proxy for the theme until its financial impact becomes clear.
The healthcare sector's current struggles are not a recent phenomenon but a five-year trend of underperformance. This has culminated in its market cap weight in the S&P 500 dropping to 9%, the lowest level in three decades, signaling a significant, long-term investor rotation away from the industry.
The 2020-2021 biotech "bubble" pushed very early-stage companies into public markets prematurely. The subsequent correction, though painful, has been a healthy reset. It has forced the sector back toward a more suitable, long-duration private funding model where companies can mature before facing public market pressures.
Early-stage biotech companies are vulnerable to short selling in public markets because their experiments run for 12-24 months, creating long periods without news flow. With no catalysts to drive buying ("no bid"), hedge funds can short the stocks until data is released, highlighting a structural disadvantage of being public too early.